MIM
CCCC icon

MetLife Investment Management’s C4 Therapeutics CCCC Stock Holding History

MetLife Investment Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
+61,393
New +$210K ﹤0.01% 2231
2025
Q2 		– Sell
-15,893
Closed -$25.4K – 2859
2025
Q1 		$25.4K Sell
15,893
-12,961
-45% -$38.7K ﹤0.01% 2737
2024
Q4 		$104K Sell
28,854
-6,601
-19% -$32.8K ﹤0.01% 2605
2024
Q3 		$202K Buy
35,455
+19,978
+129% +$120K ﹤0.01% 2282
2024
Q2 		$71.5K Buy
+15,477
New +$92.3K ﹤0.01% 2704
2023
Q2 		– Sell
-27,475
Closed -$86.3K – 2947
2023
Q1 		$86.3K Hold
27,475
– – ﹤0.01% 2609
2022
Q4 		$162K Hold
27,475
– – ﹤0.01% 2377
2022
Q3 		$241K Buy
27,475
+6,363
+30% +$66.1K ﹤0.01% 2162
2022
Q2 		$159K Hold
21,112
– – ﹤0.01% 2457
2022
Q1 		$512K Buy
21,112
+7,792
+58% +$189K ﹤0.01% 1762
2021
Q4 		$429K Hold
13,320
– – ﹤0.01% 1588
2021
Q3 		$595K Hold
13,320
– – 0.01% 1426
2021
Q2 		$504K Buy
13,320
+7,972
+149% +$286K ﹤0.01% 1564
2021
Q1 		$198K Hold
5,348
– – ﹤0.01% 2055
2020
Q4 		$177K Buy
+5,348
New +$155K ﹤0.01% 2039

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's CCCC Position: Q2 2026 in Review

MetLife Investment Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 61,393 shares worth $287K. The stake represents ﹤0.01% of the portfolio and ranks #2231 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in CCCC as recently as Q1 2025.

MetLife Investment Management first reported a position in CCCC in Q4 2020 and has held it in 15 quarters since. The position peaked at $595K in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • MetLife Investment Management held 61,393 shares of C4 Therapeutics worth $287K as of Q2 2026.
  • C4 Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2231 holding.
  • MetLife Investment Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • MetLife Investment Management's C4 Therapeutics position peaked at $595K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.